
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is a diversified healthcare company with a strong portfolio in both pharmaceuticals and MedTech. The company has a solid pipeline and is focused on M&A, while also maintaining a commitment to diversity and sustainability. Potential risks include disappointing product launches and concerns about drug pricing and tariffs, but overall, JNJ is expected to see growth and increased EPS and FCF in the coming years.
Bears say
Johnson & Johnson is a well-diversified healthcare company with a strong focus on innovation. However, the potential impact of drug patent expirations and the risks associated with its MedTech division could hinder future revenue growth. Additionally, the company may face challenges related to drug pricing and ongoing litigation. Its strong M&A focus may also bring along potential risks.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares